Intravitreal inj Adult Recommended dose: 2 mg (0.05 mL).
Wet AMD Initially 1 inj mthly for 3 consecutive doses, then extend treatment interval to 2 mth. Based on physician's judgment, treatment interval may be maintained at 2 mth or further extended using treat-&-extend regimen w/ inj intervals increased in 2- or 4-wkly increments to maintain stable visual &/or anatomic outcomes.
Macular oedema secondary to RVO (branch or central RVO) After initial inj, treatment is given mthly. Interval between 2 doses should not be shorter than 1 mth. Continue mthly treatment until max visual acuity is achieved &/or there are no signs of disease activity; ≥3 consecutive mthly inj may be needed. May continue treatment w/ treat-&-extend regimen, gradually increasing treatment intervals to maintain stable visual &/or anatomic outcomes.
DME Initially 1 inj mthly for 5 consecutive doses, followed by 1 inj every 2 mth. Based on physician's judgement, treatment interval may be maintained at 2 mth or individualized w/ treat-&-extend regimen, increasing intervals by 2-wk increments to maintain stable visual &/or anatomic outcomes.
Myopic CNV Single inj. May administer additional doses if visual &/or anatomic outcomes indicate that disease persists. Interval between 2 doses should not be shorter than 1 mth.